These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 32591088)

  • 1. Availability of dantrolene for the management of malignant hyperthermia crises: European Malignant Hyperthermia Group guidelines.
    Glahn KPE; Bendixen D; Girard T; Hopkins PM; Johannsen S; Rüffert H; Snoeck MM; Urwyler A;
    Br J Anaesth; 2020 Aug; 125(2):133-140. PubMed ID: 32591088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Stocks of dantrolene in anesthesia and intensive care units in Germany : Nationwide online survey with 1673 participants].
    Pfenninger E; Heiderich S; Klingler W
    Anaesthesist; 2017 Oct; 66(10):773-781. PubMed ID: 28660414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Consensus Statement of the Malignant Hyperthermia Association of the United States on Unresolved Clinical Questions Concerning the Management of Patients With Malignant Hyperthermia.
    Litman RS; Smith VI; Larach MG; Mayes L; Shukry M; Theroux MC; Watt S; Wong CA
    Anesth Analg; 2019 Apr; 128(4):652-659. PubMed ID: 30768455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comments on the guidelines of the European Malignant Hyperthermia Group on the availability of dantrolene for the management of malignant hyperthermia crises].
    Bastian B; Heiderich S; Schuster F; Johannsen S; Klingler W; Rüffert H
    Anaesthesist; 2020 Oct; 69(10):751-752. PubMed ID: 32936350
    [No Abstract]   [Full Text] [Related]  

  • 5. Malignant hyperthermia.
    Ben Abraham R; Adnet P; Glauber V; Perel A
    Postgrad Med J; 1998 Jan; 74(867):11-7. PubMed ID: 9538480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Succinylcholine Use and Dantrolene Availability for Malignant Hyperthermia Treatment: Database Analyses and Systematic Review.
    Larach MG; Klumpner TT; Brandom BW; Vaughn MT; Belani KG; Herlich A; Kim TW; Limoncelli J; Riazi S; Sivak EL; Capacchione J; Mashman D; Kheterpal S; Kooij F; Wilczak J; Soto R; Berris J; Price Z; Lins S; Coles P; Harris JM; Cummings KC; Berman MF; Nanamori M; Adelman BT; Wedeven C; LaGorio J; McCormick PJ; Tom S; Aziz MF; Coffman T; Ellis TA; Molina S; Peterson W; Mackey SC; van Klei WA; Ginde AA; Biggs DA; Neuman MD; Craft RM; Pace NL; Paganelli WC; Durieux ME; Nair BJ; Wanderer JP; Miller SA; Helsten DL; Turnbull ZA; Schonberger RB;
    Anesthesiology; 2019 Jan; 130(1):41-54. PubMed ID: 30550426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Malignant Hyperthermia in a Morbidly Obese Patient Depletes Community Dantrolene Resources: A Case Report.
    Magistris F; Gamble J
    A A Case Rep; 2017 Nov; 9(9):251-253. PubMed ID: 28697029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacological Treatment of Malignant Hyperthermia: Update 2019].
    Schuster F; Johannsen S
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2019 Sep; 54(9):549-558. PubMed ID: 31525788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Malignant hyperthermia].
    Bouhajja B; Haddad F; Ben Ammar MS
    Tunis Med; 2002 Jul; 80(7):395-401. PubMed ID: 12611349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Malignant hyperthermia 2020: Guideline from the Association of Anaesthetists.
    Hopkins PM; Girard T; Dalay S; Jenkins B; Thacker A; Patteril M; McGrady E
    Anaesthesia; 2021 May; 76(5):655-664. PubMed ID: 33399225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mixing and using dantrolene for simulated malignant hyperthermia crisis.
    Corvetto MA; Montaña R; Bravo MP; Altermatt FR
    Acta Anaesthesiol Scand; 2012 Nov; 56(10):1337-8. PubMed ID: 22881345
    [No Abstract]   [Full Text] [Related]  

  • 12. Dantrolene--a review of its pharmacology, therapeutic use and new developments.
    Krause T; Gerbershagen MU; Fiege M; Weisshorn R; Wappler F
    Anaesthesia; 2004 Apr; 59(4):364-73. PubMed ID: 15023108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malignant hyperthermia when dantrolene is not readily available.
    Gong X
    BMC Anesthesiol; 2021 Apr; 21(1):119. PubMed ID: 33863282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recognizing and treating malignant hyperthermia.
    Corvetto MA; Taekman JM
    Simul Healthc; 2010 Jun; 5(3):169-72. PubMed ID: 20651479
    [No Abstract]   [Full Text] [Related]  

  • 15. Drawing up dantrolene for the treatment of malignant hyperthermia: use of a drawing up spike to make the process easier and quicker.
    Storey M; Hardy R; Kelly FE
    Anaesthesia; 2020 Jun; 75(6):835. PubMed ID: 32383516
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost-benefit Analysis of Maintaining a Fully Stocked Malignant Hyperthermia Cart versus an Initial Dantrolene Treatment Dose for Maternity Units.
    Ho PT; Carvalho B; Sun EC; Macario A; Riley ET
    Anesthesiology; 2018 Aug; 129(2):249-259. PubMed ID: 29672336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secretion of dantrolene into breast milk after acute therapy of a suspected malignant hyperthermia crisis during cesarean section.
    Fricker RM; Hoerauf KH; Drewe J; Kress HG
    Anesthesiology; 1998 Oct; 89(4):1023-5. PubMed ID: 9778021
    [No Abstract]   [Full Text] [Related]  

  • 18. Malignant hyperthermia in a young adolescent: A case report.
    Toh H; Shahani JM; Ali AJ
    Natl Med J India; 2014; 27(5):259-60. PubMed ID: 26037425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [S1 guidelines on malignant hyperthermia : Update 2018].
    Wappler F
    Anaesthesist; 2018 Jul; 67(7):529-532. PubMed ID: 29943228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-cost, easy-to-make simulated dantrolene for malignant hyperthermia scenarios.
    Boet S
    Acta Anaesthesiol Scand; 2014 Mar; 58(3):372-3. PubMed ID: 25237700
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.